[Federal Register Volume 66, Number 141 (Monday, July 23, 2001)]
[Notices]
[Page 38323]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 01-18214]



[[Page 38323]]

-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to section 1301.33(a) of title 21 of the Code of Federal 
Regulations (CFR), this is notice that on March 7, 2001, Abbott 
Laboratories, DBA Knoll Pharmaceutical Company, 30 North Jefferson 
Road, Whippany, New Jersey 07981, made application to the Drug 
Enforcement Administration (DEA) for registration as a bulk 
manufacturer of the basic classes of controlled substances listed 
below:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Dihydromorphine (9145).....................  I
Hydromorphone (9150).......................  II
------------------------------------------------------------------------

    The firm plans to produce bulk product and finished dosage units 
for distribution to its customers.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such substances may file comment or objections 
to the issuance of the proposed registration.
    Any such comments or objections may be addressed, in quintuplicate, 
to the Deputy Assistant Administrator, Office of Diversion Control, 
Drug Enforcement Administration, United States Department of Justice, 
Washington, DC 20537, Attention: DEA Federal Register Representative 
(CCR), and must be filed no later than September 21, 2001.

    Dated: July 13, 2001.
Laura M. Nagel,
Deputy Assitant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 01-18214 Filed 7-20-01; 8:45 am]
BILLING CODE 4410-09-M